Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Moreover, we observed a direct relationship between ΔsGlu and ΔLDL-chol in Zol-treated patients (r = 0.245, p = 0.02) whereas no relationship was observed between Δ25OHD and ΔGlu (r = − 0.22, p = 0.15), ΔLDL (r = − 0.18, p = 0.45), ΔtChol (r = − 0.20, p = 0.41), ΔHDL (r = − 0.19, p = 0.42), and ΔTry (r = − 0.26, p = 0.10).Biochemical parameters of the three study cohorts before and after bisphosphonate treatmentPDB-ZolPDB-CloOp-ZolT0T1T6T0T1T6T0T1T6Crea (μmol/l)79.6 ± 31.381.1 ± 32.180.3 ± 31.280.9 ± 29.282.9 ± 30.379.6 ± 30.180.9 ± 30.682.1 ± 31.279.9 ± 29.9Glu (mmol/l)5.19 ± 0.584.98 ± 0.54a4.91 ± 0.52a5.23 ± 0.525.41 ± 0.515.27 ± 0.545.25 ± 0.514.97 ± 0.51a4.90 ± 0.49atCa (mmol/l)2.37 ± 0.132.29 ± 0.122.32 ± 0.122.41 ± 0.142.29 ± 0.132.40 ± 0.132.34 ± 0.132.21 ± 0.122.32 ± 0.13t-chol (mmol/l)5.10 ± 1.064.89 ± 1.02a4.71 ± 1.01a5.29 ± 0.995.18 ± 1.065.23 ± 1.055.09 ± 1.024.86 ± 1.05a4.72 ± 1.03aHDL-chol (mmol/l)1.32 ± 0.411.31 ± 0.421.31 ± 0.431.49 ± 0.411.39 ± 0.421.39 ± 0.411.51 ± 0.391.50 ± 0.411.50 ± 0.39LDL-chol (mmol/l)3.10 ± 0.962.98 ± 0.89a2.83 ± 0.86a3.10 ± 0.833.11 ± 0.823.16 ± 0.852.92 ± 0.812.76 ± 0.82a2.66 ± 0.79aTG (mmol/l)1.49 ± 0.801.32 ± 0.821.25 ± 0.81a1.53 ± 0.861.48 ± 0.821.50 ± 0.811.46 ± 0.781.31 ± 0.801.24 ± 0.80a25OHD (nmol/l)84.3 ± 18.782.4 ± 19.183.7 ± 17.889.1 ± 18.488.4 ± 18.187.1 ± 17.285.1 ± 17.683.4 ± 17.881.6 ± 16.9ALP (%)155 ± 90b87 ± 32a78 ± 27a148 ± 84b114 ± 58a83 ± 36a75 ± 2267 ± 2165 ± 26Data are expressed as mean ± standard deviationPDB-Zol patients with Paget’s disease of bone treated with zoledronic acid, PDB-Clo patients with Paget’s disease of bone treated with clodronic acid, Op-Zol patients with osteoporosis treated with zoledronic acid, T0 before zoledronic or clodronic acid treatment, T1 1 month after zoledronic or clodronic acid treatment, T6 6 months after zoledronic or clodronic acid treatment, Crea creatinine, Glu glycemia, tCa total calcium, t-chol total cholesterol, HDL-chol high-density lipoprotein-cholesterol, LDL-chol low-density lipoprotein-cholesterol, TG triglycerides, 25OHD 25OH-vitamin D, ALP total alkaline phosphataseaSignificantly different compared to T0 (p < 0.05; t test for paired samples)bSignificantly different compared to Op-Zol patients (p < 0.05; analysis of variance with Bonferroni correction)Differences from baseline in blood lipids and glucose levels in patients with Paget’s disease of bone treated for the first time with bisphosphonate (black columns) or in PDB patients previously treated with bisphosphonate (gray columns).

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In this retrospective cohort study, we evaluated the effects of an intravenous infusion of zoledronic acid (5 mg) or clodronic acid (1500 mg) on blood lipid (i.e.

Source: Abstract.

On their first admission, all patients were informed that (i) their personal data, collected as part of administrative management and hospital care, could be used for health research purposes, under the responsibility of the Federico II University of Naples and of Siena University; (ii) they could withdraw their consent to the use of personal data without providing further explanation at any time and without medical assistance being affected.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders

Cohort study · Calcified Tissue International · 2021

Original publication title

Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders

Gabriella Iannuzzo; Gianpaolo De Filippo; Daniela Merlotti; Veronica Abate; Alessio Buonaiuto; Marco Evangelista; Marco Gentile; Alfonso Giaquinto; Tommaso Picchioni; Matteo Nicola Dario Di Minno; Pasquale Strazzullo; Luigi Gennari; Domenico Rendina

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Bisphosphonates are the first-choice treatment of osteoporosis and Paget’s disease of bone. Among the bisphosphonates, the non-amino-bisphosphonates, such as clodronic acid, are intracellular converted into toxic analogues of ATP and induce cellular apoptosis whereas the amino-bisphosphonates, such as zoledronic acid, inhibit the farnesyl-diphosphate-synthase, an enzyme of the mevalonate pathway. This pathway regulates cholesterol and glucose homeostasis and is a target for statins. In this retrospective cohort study, we evaluated the effects of an intravenous infusion of zoledronic acid (5 mg) or clodronic acid (1500 mg) on blood lipid (i.e. total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglycerides) and glucose levels in patients with osteoporosis and Paget’s disease of bone.

All patients were evaluated before, 1 and 6 months after bisphosphonate treatment. Pagetic and osteoporotic patients treated with zoledronic acid showed a significant reduction in glucose and atherogenic lipids during follow-up whereas these phenomena were not observed after clodronic treatment. The effect on circulating lipid levels was similar in naïve and re-treated Pagetic patients. Zoledronic acid treatment was associated with a reduction in blood glucose and atherogenic lipids in patients with metabolic bone disorders. The extent of change was similar to that obtained with the regular assumption of a low-intensity statin.

Further studies are warranted to better evaluate the clinical implications of these observations.

Supplementary Information

The online version of this article (10.1007/s00223-021-00811-w) contains supplementary material, which is available to authorized users.

Authors’ abstract

Bisphosphonates are the first-choice treatment of osteoporosis and Paget’s disease of bone. Among the bisphosphonates, the non-amino-bisphosphonates, such as clodronic acid, are intracellular converted into toxic analogues of ATP and induce cellular apoptosis whereas the amino-bisphosphonates, such as zoledronic acid, inhibit the farnesyl-diphosphate-synthase, an enzyme of the mevalonate pathway. This pathway regulates cholesterol and glucose homeostasis and is a target for statins. In this retrospective cohort study, we evaluated the effects of an intravenous infusion of zoledronic acid (5 mg) or clodronic acid (1500 mg) on blood lipid (i.e. total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglycerides) and glucose levels in patients with osteoporosis and Paget’s disease of bone.

All patients were evaluated before, 1 and 6 months after bisphosphonate treatment. Pagetic and osteoporotic patients treated with zoledronic acid showed a significant reduction in glucose and atherogenic lipids during follow-up whereas these phenomena were not observed after clodronic treatment. The effect on circulating lipid levels was similar in naïve and re-treated Pagetic patients. Zoledronic acid treatment was associated with a reduction in blood glucose and atherogenic lipids in patients with metabolic bone disorders. The extent of change was similar to that obtained with the regular assumption of a low-intensity statin.

Further studies are warranted to better evaluate the clinical implications of these observations.

Supplementary Information

The online version of this article (10.1007/s00223-021-00811-w) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders

Gabriella Iannuzzo; Gianpaolo De Filippo; Daniela Merlotti; Veronica Abate; Alessio Buonaiuto; Marco Evangelista; Marco Gentile; Alfonso Giaquinto; Tommaso Picchioni; Matteo Nicola Dario Di Minno; Pasquale Strazzullo; Luigi Gennari; Domenico Rendina

Calcified Tissue International · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Napoli Federico II

Open Access funding provided by Università degli Studi di Napoli Federico II

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:28:36.857416+00:00

DOI: 10.1007/s00223-021-00811-w · PMC8166716